RLMD vs CING โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
RLMD Captures Institutional Edge (2โ1 Pillars ยท 3โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Relmada Therapeutics, Inc. Common Stock (RLMD) driven by superior Growth & Margin, Options & Structure while CING counters with relative strength in Momentum & Technical. Fundamentally, RLMD trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus CING at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, RLMD sits in BREAKDOWN (36th %ile IV; Dealer Gamma Walls on Pro) against CING sits in BREAKDOWN (16th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | RLMD | CING | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $449.2M | $62.5M | Larger Scale | RLMD |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +0.0% | +0.0% | Higher Growth | Tie |
| Operating Margin (TTM) Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -64.7% | -198.7% | Higher ROE | RLMD |
| 52-Week Range Position Momentum | 0% ($3โ$8) | 18% ($3โ$12) | Stronger Trend | CING |
| Beta / 30D Volatility Risk Regime | 1.69ฮฒ ยท 107% Vol | 1.07ฮฒ ยท 121% Vol | Lower Realized Risk | RLMD |
| Unified Institutional Score Composite Signal | 39.0 / 100 (SELL) | 44.8 / 100 (HOLD) | Higher Composite | CING |